Step by Step
Why
Why fungi are a harder target than bacteria
Fungi are eukaryotic cells, just like human cells — unlike bacteria, which are structurally very different from us. That similarity means there are far fewer unique fungal targets a drug can hit without also damaging human cells, which is why antifungal drugs are generally more limited in number and more prone to toxicity than antibacterial drugs.
Erg
Ergosterol — the fungal cell membrane's key molecule
Ergosterol is the fungal equivalent of cholesterol in the human cell membrane — a good drug target specifically because human cells use cholesterol instead. Azoles (like fluconazole) work by blocking ergosterol synthesis. Amphotericin B works differently, binding ergosterol directly and creating pores in the fungal membrane — but this drug is highly nephrotoxic, since ergosterol and cholesterol are similar enough that some off-target binding to human cell membranes occurs.
Ech
Echinocandins — targeting the fungal cell wall
Echinocandins (like caspofungin) block beta-glucan synthase, an enzyme fungi use to build their cell wall — a structure human cells don't have at all, making this a very selective target with fewer side effects.
5FC
Flucytosine — hijacking fungal metabolism
Flucytosine is converted inside fungal cells into 5-fluorouracil (5-FU), which then inhibits fungal DNA synthesis — again exploiting a fungal-specific metabolic conversion that doesn't happen the same way in human cells.
A patient being treated for a severe invasive fungal infection with amphotericin B needs close monitoring of renal function throughout treatment, since the drug's mechanism — binding ergosterol and creating membrane pores — carries a real risk of nephrotoxicity given how structurally similar ergosterol and human cholesterol actually are.
Applied Walkthrough
1
A patient with a severe, invasive fungal infection is started on amphotericin B, and the care team is closely monitoring kidney function throughout treatment.
2
Ask: why does this particular antifungal require such close monitoring, when other antifungals don't carry the same risk to the same degree? Amphotericin B binds ergosterol directly and forms pores in the fungal membrane — but because ergosterol closely resembles human cholesterol, some of that pore-forming activity affects human cell membranes too, particularly in the kidneys.
3
Contrast: an echinocandin like caspofungin targets the fungal cell wall (beta-glucan synthase) — a structure with no human equivalent at all, which is why echinocandins tend to have a much more favorable side-effect profile than amphotericin B.
4
This contrast illustrates the core theme of antifungal pharmacology: drugs that hit purely fungal-specific structures (like the cell wall) tend to be safer, while drugs that must target something structurally similar to a human component (like ergosterol vs. cholesterol) tend to carry more collateral toxicity.
Exam Application
Exams test the underlying reason antifungals are harder to develop safely (fungi are eukaryotic, sharing more structural similarity with human cells than bacteria do), and matching each drug class to its specific target: azoles and amphotericin B target ergosterol, echinocandins target beta-glucan synthase (cell wall), and flucytosine is converted to 5-FU to block DNA synthesis.
⚠ Common Trap
The most common trap is assuming all antifungals carry the same risk profile as amphotericin B. Echinocandins, which target the fungal-specific cell wall rather than a structure resembling a human component, are considerably safer — conflating the two ignores an important distinction in target selectivity that directly explains their different side-effect profiles.
✓ Quick Self-Check
1. Why are fungal infections generally harder to treat safely than bacterial infections?
Because fungi are eukaryotic cells, structurally similar to human cells, leaving fewer unique targets a drug can hit without also affecting human cells.
Tap to reveal / hide
2. What is ergosterol, and why is it a useful drug target?
The fungal cell membrane equivalent of human cholesterol; it's useful because human cells use cholesterol instead, giving some selectivity, though not perfect selectivity.
Tap to reveal / hide
3. How do azoles and amphotericin B differ in how they act on ergosterol?
Azoles block ergosterol synthesis; amphotericin B binds ergosterol directly, creating pores in the fungal membrane.
Tap to reveal / hide
4. Why is amphotericin B nephrotoxic?
Because ergosterol closely resembles human cholesterol, so some of the pore-forming activity also affects human cell membranes, particularly in the kidneys.
Tap to reveal / hide
5. What do echinocandins target, and why do they tend to have a better safety profile than amphotericin B?
They block beta-glucan synthase, targeting the fungal cell wall — a structure with no human equivalent, giving much better selectivity than a target like ergosterol.
Tap to reveal / hide